



July 14, 2000 / Vol. 49 / No. RR-8

MMWRTM
MORBIDITY AND MORTALITY
WEEKLY REPORT

***Recommendations
and
Reports***

**Compendium of Measures To Control
Chlamydia psittaci Infection Among
Humans (Psittacosis) and Pet Birds
(Avian Chlamydiosis), 2000**

and

**Compendium of Animal Rabies
Prevention and Control, 2000**

**National Association of State
Public Health Veterinarians, Inc.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Atlanta, Georgia 30333



The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION

Centers for Disease Control and Prevention. Compendium of measures to control *Chlamydia psittaci* infection among humans (psittacosis) and pet birds (avian chlamydiosis), 2000 and Compendium of animal rabies prevention and control, 2000: National Association of State Public Health Veterinarians, Inc. *MMWR* 2000;49(No. RR-8):[inclusive page numbers].

Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.
Director

The material in this report was prepared for publication by
National Center for Infectious Diseases James M. Hughes, M.D.
Director

Division of Bacterial and Mycotic Diseases Mitchell L. Cohen, M.D.
Director

Division of Viral and Rickettsial Diseases James W. Le Duc, Ph.D.
Acting Director

The production of this report as an *MMWR* serial publication was coordinated in
Epidemiology Program Office Barbara R. Holloway, M.P.H.
Acting Director

Office of Scientific and Health Communications John W. Ward, M.D.
Director
Editor, MMWR Series

Recommendations and Reports Suzanne M. Hewitt, M.P.A.
Managing Editor

Valerie R. Johnson
Patricia A. McGee
Project Editors

Beverly J. Holland
Visual Information Specialist

Michele D. Renshaw
Erica R. Shaver
Information Technology Specialists

Contents

Compendium of Measures To Control <i>Chlamydia psittaci</i> Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2000	1
Introduction	3
Part I. Infection Among Humans (Psittacosis)	4
Transmission	4
Clinical Signs and Symptoms	4
Case Definitions	5
Diagnosis	5
Laboratories that Test Human Specimens for <i>C. psittaci</i>	5
Treatment	6
Part II. Infection Among Birds (Avian Chlamydiosis)	6
Transmission	6
Clinical Signs	6
Case Definitions	7
Diagnosis	7
Treatment	7
Part III. Recommendations and Requirements	7
Recommendations for Controlling Infection Among Humans and Birds ..	7
Recommendations for Treating and Caring for Infected Birds	9
Responsibilities of Physicians and Veterinarians	9
Quarantine of Birds	10
Bird Importation Regulations	10
Local and State Epidemiologic Investigations	11
References	11
Additional Resources	11
Appendix A: Methods for Diagnosing Avian Chlamydiosis	12
Pathologic Findings	12
Culture Technique	12
Tests for Antibody	12
Tests for Antigen	13
Additional Tests	13
Laboratories that Test Avian Specimens for <i>C. psittaci</i>	14
Appendix B: Treatment Options for Pet Birds with Avian Chlamydiosis	15
Medicated Feed	15
Medicated Water	15
Oral Doxycycline	16
Injectable Doxycycline	16
Injectable Oxytetracycline	16
Experimental Methods	16
Sources of Medications	16

Compendium of Animal Rabies Prevention and Control, 2000: National Association of State Public Health Veterinarians, Inc.	19
Part I: Recommendations for Parenteral Immunization Procedures	21
A. Vaccine Administration	21
B. Vaccine Selection	21
C. Route of Inoculation	22
D. Vaccination of Wildlife and Hybrid Animals	22
E. Accidental Human Exposure to Vaccine	22
F. Identification of Vaccinated Animals	22
Part II: Rabies Vaccines Licensed and Marketed in the United States and NASPHV Recommendations, 2000	23
A. Monovalent (Inactivated)	23
B. Monovalent (Rabies glycoprotein, live canary pox vector)	24
C. Combination (Inactivated rabies)	24
D. Combination (Rabies glycoprotein, live canary pox vector)	25
E. Oral (Rabies glycoprotein, live vaccinia vector)	25
Part III: Rabies Control	26
A. Principles of Rabies Control	26
B. Control Methods in Domestic and Confined Animals	26
C. Control Methods in Wildlife	29

NOTICE

This report is being published as a courtesy to both the National Association of State Public Health Veterinarians, Inc., and to the *MMWR* readership. Its publication does not imply endorsement by CDC.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the National Association of State Public Health Veterinarians, Council of State and Territorial Epidemiologists, Association of Avian Veterinarians, American Veterinary Medical Association, or the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

Compendium of Measures To Control *Chlamydia psittaci* Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2000

Committee of the National Association of State Public Health Veterinarians

William B. Johnston, D.V.M., Dpl. ACVPM, Chair
Alabama Department of Public Health

Millicent Eidson, M.A., D.V.M., Dpl. ACVPM
New York State Department of Health

Kathleen A. Smith, D.V.M., M.P.H.
Ohio Department of Health

Mary Grace Stobierski, D.V.M., M.P.H., Dpl. ACVPM
Michigan Department of Community Health

Consultants to the Committee

Richard E. Besser, M.D.
Centers for Disease Control and Prevention

Lisa A. Conti, D.V.M., M.P.H., Dpl. ACVPM
Council of State and Territorial Epidemiologists

Keven Flammer, D.V.M., Dpl. ABVP (Avian)
Association of Avian Veterinarians

Kevin F. Reilly, D.V.M., M.P.V.M.
*American Veterinary Medical Association's
Council on Public Health and Regulatory Medicine*

Branson Ritchie, D.V.M., Ph.D., Dpl. ABVP (Avian)
Association of Avian Veterinarians

Thomas N. Tully, Jr., D.V.M., M.S., Dpl. ABVP (Avian)
Association of Avian Veterinarians

This report is endorsed by the American Veterinary Medical Association, Council of State and Territorial Epidemiologists, and Association of Avian Veterinarians. Address all correspondence to William B. Johnston, D.V.M., Alabama Department of Public Health, Division of Epidemiology, Suite 1310, P.O. Box 303017; Montgomery, AL 36130-3017. Copies also can be accessed at the CDC website at <<http://www.cdc.gov/ncidod>> and the American Veterinary Medical Association website at <<http://www.avma.org>>.

Compendium of Measures To Control *Chlamydia psittaci* Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2000

Summary

Psittacosis — also known as parrot fever and ornithosis — is spread by a bacterial infection of birds that can cause severe pneumonia and other serious health problems among humans. From 1988 through 1998, 813 cases of psittacosis (infection with *Chlamydia psittaci*) were reported to CDC, and most resulted from exposure to infected pet birds, usually cockatiels, parakeets, parrots, and macaws. In birds, *C. psittaci* infection is referred to as avian chlamydiosis (AC). Infected birds shed the bacteria through feces and nasal discharges, and humans become infected from exposure to these materials. This compendium provides information about psittacosis and AC to public health officials, physicians, veterinarians, the pet bird industry, and others concerned about controlling these diseases and protecting public health. The recommendations in this compendium provide standardized procedures for controlling AC in birds, a vital step to protecting human health.

INTRODUCTION

Chlamydia psittaci is a bacterium that can be transmitted from pet birds to humans. In humans, the resulting infection is referred to as psittacosis (also known as parrot fever and ornithosis). Psittacosis typically causes influenza-like symptoms and can lead to severe pneumonia and nonrespiratory health problems. With appropriate treatment, the disease is rarely fatal. From 1988 through 1998, CDC received reports of 813 cases of psittacosis (1), which is an underrepresentation of the actual number of cases because psittacosis is difficult to diagnose and cases often go unreported. During the 1980s, approximately 70% of the psittacosis cases with a known source of infection resulted from exposure to pet birds. The largest group affected (43%) included bird fanciers and owners of pet birds. Pet shop employees accounted for an additional 10% of cases. Other persons at risk include pigeon fanciers and persons whose occupation places them at risk for exposure (e.g., employees in poultry slaughtering and processing plants, veterinarians, veterinary technicians, laboratory workers, workers in avian quarantine stations, farmers, wildlife rehabilitators, and zoo workers). Because human infection can result from brief, passing exposure to infected birds or their contaminated droppings, persons with no identified leisure-time or occupational risk can become infected.

In this report, *C. psittaci* infection in birds is referred to as avian chlamydiosis (AC). *C. psittaci* has been isolated from approximately 100 bird species but is most commonly identified in psittacine (parrot-type) birds, especially cockatiels and parakeets. Among caged, nonpsittacine birds, infection with *C. psittaci* occurs most frequently in pigeons, doves, and mynah birds. AC is less frequently diagnosed in canaries and finches.

The recommendations in this compendium provide standardized procedures for controlling AC in the pet bird population, an essential step in efforts to control psittacosis among humans. Development of and participation in aviary and pet shop accreditation programs is encouraged. This compendium is intended to guide public health officials, physicians, veterinarians, the pet bird industry, and others concerned with the control of *C. psittaci* infection and the protection of public health.

PART I. INFECTION AMONG HUMANS (PSITTACOSIS)

Transmission

Because several diseases affecting humans can be caused by other species of *Chlamydia*, the disease resulting from the infection of humans with *C. psittaci* is referred to as psittacosis. Most *C. psittaci* infections in humans result from exposure to pet psittacine birds. However, transmission has been documented from free-ranging birds, including doves, pigeons, birds of prey, and shore birds. Infection with *C. psittaci* usually occurs when a person inhales the organism, which has been aerosolized from dried feces or respiratory secretions of infected birds. Other means of exposure include mouth-to-beak contact and the handling of infected birds' plumage and tissues. Even brief exposures can lead to symptomatic infection; therefore, some patients with psittacosis might not recall or report having any contact with birds.

Mammals occasionally transmit *C. psittaci* to humans. Certain strains of *C. psittaci* infect sheep, goats, and cattle, causing chronic infection of the reproductive tract, placental insufficiency, and abortion in these animals. These strains of *C. psittaci* are transmitted to persons when they are exposed to the birth fluids and placentas of infected animals. Another strain of *C. psittaci*, feline keratoconjunctivitis agent, typically causes rhinitis and conjunctivitis in cats. Transmission of this strain from cats to humans rarely occurs.

Person-to-person transmission has been suggested but not proven. Standard infection-control precautions are sufficient for patients with psittacosis, and specific isolation procedures (e.g., private room, negative pressure air flow, and masks) are not indicated.

Clinical Signs and Symptoms

The onset of illness typically follows an incubation period of 5–14 days, but longer periods have been reported. The severity of this disease ranges from inapparent illness to systemic illness with severe pneumonia. Before antimicrobial agents were available, 15%–20% of persons with *C. psittaci* infection died. However, <1% of properly treated patients now die as a result of the infection.

Persons with symptomatic infection typically have abrupt onset of fever, chills, headache, malaise, and myalgia. They usually develop a nonproductive cough that can be accompanied by breathing difficulty and chest tightness. A pulse-temperature dissociation (fever without elevated pulse), enlarged spleen, and rash are sometimes observed and are suggestive of psittacosis in patients with community-acquired pneumonia. Auscultatory findings can underestimate the extent of pulmonary involvement. Radiographic findings include lobar or interstitial infiltrates. The differen-

tial diagnosis of psittacosis-related pneumonia includes infection with *Coxiella burnetii*, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Legionella* species, and respiratory viruses such as influenza. *C. psittaci* can affect organ systems other than the respiratory tract and result in endocarditis, myocarditis, hepatitis, arthritis, keratoconjunctivitis, and encephalitis. Severe illness with respiratory failure, thrombocytopenia, hepatitis, and fetal death has been reported among pregnant women.

Case Definitions

In 1997, CDC and the Council of State and Territorial Epidemiologists established case definitions for confirmed and probable psittacosis for epidemiologic purposes (2). These definitions should not be used as the sole criteria for establishing clinical diagnoses. A patient is considered to have a *confirmed* case of psittacosis if clinical illness is compatible with psittacosis and the case is laboratory confirmed by one of three methods: a) *C. psittaci* is cultured from respiratory secretions; b) antibody against *C. psittaci* is increased by fourfold or greater (to a reciprocal titer of 32 between paired acute- and convalescent-phase serum specimens collected at least 2 weeks apart) as demonstrated by complement fixation (CF) or microimmunofluorescence (MIF); or c) immunoglobulin M antibody is detected against *C. psittaci* by MIF (to a reciprocal titer of 16). A patient is considered to have a *probable* case of psittacosis if clinical illness is compatible with psittacosis and a) the patient is epidemiologically linked to a confirmed human case of psittacosis or b) a single antibody titer of 32, demonstrated by CF or MIF, is present in at least one serum specimen obtained after onset of symptoms.

Diagnosis

Most diagnoses are established by using serologic methods in which paired sera are tested for chlamydial antibodies by CF test. However, because chlamydial CF antibody is not species-specific, high CF titers also can result from *C. pneumoniae* and *C. trachomatis* infections. Acute-phase serum specimens should be obtained as soon as possible after onset of symptoms, and convalescent-phase serum specimens should be obtained 2 weeks after onset of symptoms. Because antibiotic treatment can delay or diminish the antibody response, a third serum sample might help confirm the diagnosis. All sera should be tested simultaneously at the same laboratory. If the patient's epidemiologic and clinical history indicate a possible diagnosis of psittacosis, MIF and polymerase chain reaction (PCR) assays can be used to distinguish *C. psittaci* infection from infection with other chlamydial species. The infectious agent also can be isolated from the patient's sputum, pleural fluid, or clotted blood during acute illness and before treatment with antimicrobial agents; however, culture of *C. psittaci* is performed by few laboratories because of technical difficulty and safety concerns.

Laboratories that Test Human Specimens for *C. psittaci*

Information about laboratory testing is available from most state public health laboratories. Few commercial laboratories have the capability to differentiate *Chlamydia* species. The following laboratories (Table 1) accept human specimens to confirm *C. psittaci*. Other sources might be available.

TABLE 1. Laboratories that test human specimens for *Chlamydia psittaci*

Laboratory	Tests performed*	Phone number
Respiratory Diseases Laboratory Section, CDC, Atlanta, Georgia	<ul style="list-style-type: none"> • MIF • CF • PCR • Culture 	(404) 639-3563
Microbiology Research Labs, Cypress, California	<ul style="list-style-type: none"> • IFA • PCR • Culture 	(800) 445-4032
Laboratory Corp of America, Burlington, North Carolina	<ul style="list-style-type: none"> • Culture • Polyclonal antibody 	(800) 334-5161
Specialty Labs, Santa Monica, California	<ul style="list-style-type: none"> • MIF 	(800) 421-4449

* CF = complement fixation; IFA = immunofluorescent antibody tests; MIF = microimmunofluorescence; PCR = polymerase chain reaction.

Treatment

Tetracyclines are the drugs of choice (3). Most patients respond to oral therapy (100 mg of doxycycline administered twice a day or 500 mg of tetracycline hydrochloride administered four times a day). For initial treatment of severely ill patients, doxycycline hyclate can be administered intravenously at a dosage of 4.4 mg/kg (2 mg/lb) body weight per day divided into two infusions per day (up to 100 mg per dose). Remission of symptoms usually is evident within 48–72 hours. However, relapse can occur, and treatment must continue for at least 10–14 days after fever abates. Although its in vivo efficacy has not been determined, erythromycin probably is the best alternative agent in patients for whom tetracycline is contraindicated (e.g., children aged <9 years and pregnant women).

PART II. INFECTION AMONG BIRDS (AVIAN CHLAMYDIOSIS)

Transmission

C. psittaci is excreted in the feces and nasal discharges of infected birds. The organism is resistant to drying and can remain infectious for several months. If infected, birds can appear healthy and shed the organism intermittently. Shedding can be activated by stress factors, including shipping, crowding, chilling, and breeding (3).

Clinical Signs

The time between exposure to *C. psittaci* and onset of illness ranges from 3 days to several weeks. However, active disease can appear years after exposure. Whether the bird exhibits acute or chronic signs of illness or dies depends on the species of bird, virulence of the strain, infectious dose, stress factors, age, and extent of treatment or prophylaxis (4).

Signs of AC include lethargy, anorexia, and ruffled feathers, similar to signs of other systemic illnesses. Other signs include serous or mucopurulent ocular or nasal discharge, diarrhea, and excretion of green to yellow-green urates. Anorectic birds can produce sparse, dark green droppings, followed by emaciation, dehydration, and death.

Case Definitions

A *confirmed* case of AC is defined on the basis of at least one of the following laboratory results: a) isolation of *C. psittaci* from a clinical specimen, b) identification of chlamydial antigen by immunofluorescence (fluorescent antibody [FA]) of the bird's tissues, c) a greater than fourfold change in serologic titer in two specimens from the bird obtained at least 2 weeks apart and assayed simultaneously at the same laboratory, or d) identification of *C. psittaci* within macrophages in smears stained with Gimenez or Macchiavellos stain or sections of the bird's tissues.

A *probable* case of AC is defined as compatible illness and at least one of the following laboratory results: a) a single high serologic titer in one or more specimens obtained after the onset of signs or b) the presence of *C. psittaci* antigen (identified by enzyme-linked immunosorbent assay [ELISA], PCR, or FA) in feces, a cloacal swab, or respiratory or ocular exudates.

A *suspected* case of AC is defined as a) compatible illness that is epidemiologically linked to another case in a human or bird but that is not laboratory confirmed, b) a subclinical infection with a single high serologic titer or detection of chlamydial antigen, c) compatible illness with positive results from a nonstandardized test or a new investigational test, or d) compatible illness that is responsive to appropriate therapy.

Diagnosis

Several diagnostic methods are available for identifying AC in birds (Appendix A).

Treatment

Treatment should be supervised by a licensed veterinarian (Appendix B).

PART III. RECOMMENDATIONS AND REQUIREMENTS

Recommendations for Controlling Infection Among Humans and Birds

To prevent transmission of *C. psittaci* to persons and birds, the following control measures are recommended:

- **Protect persons at risk.** Inform all persons in contact with infected birds about the nature of the disease. Instruct them to wear protective clothing, gloves, a disposable surgical cap, and a respirator with an N95 rating or a higher-efficiency respirator when cleaning cages or handling infected birds. Surgical masks might not be effective in preventing transmission of *C. psittaci*. When necropsies are performed on potentially infected birds, wet the carcass with detergent and water to prevent aerosolization of infectious particles and work under a biological safety cabinet (or equivalent).

- **Maintain accurate records of all bird-related transactions to aid in identifying sources of infected birds and potentially exposed persons.** Records should include the date of purchase, species of birds purchased, source of birds, and any identified illnesses or deaths among birds. In addition, the seller should record the name, address, and telephone number of the customer and the band numbers if applicable.
- **Avoid purchasing or selling birds that have signs of AC.** Signs include ocular or nasal discharge, diarrhea, or low body weight.
- **Isolate newly acquired birds.** Isolate the birds — including those that have been to shows, exhibitions, fairs, and other events — for 30–45 days, and test or prophylactically treat them before adding them to a group.
- **Test birds before they are to be boarded or sold on consignment.** House them in a room separate from other birds.
- **Practice preventive husbandry.** Position cages to prevent the transfer of fecal matter, feathers, food, and other materials from one cage to another. Do not stack cages, and be sure to use solid-sided cages or barriers if cages are adjoining. The bottom of the cage should be made of a wire mesh. Litter that will not produce dust (e.g., newspapers) should be placed underneath the mesh. Clean all cages, food bowls, and water bowls daily. Soiled bowls should be emptied, cleaned with soap and water, rinsed, placed in a disinfectant solution, and rinsed again before reuse. Between occupancies by different birds, cages should be thoroughly scrubbed with soap and water, disinfected, and rinsed in clean, running water. Exhaust ventilation should be sufficient to prevent accumulation of aerosols.
- **Prevent the spread of infection.** Isolate birds requiring treatment. Rooms and cages where infected birds were housed should be cleaned immediately and disinfected thoroughly. When the cage is being cleaned, transfer the bird to a clean cage. Thoroughly scrub the soiled cage with a detergent to remove all fecal debris, rinse the cage, disinfect it (allowing at least 5 minutes of contact with the disinfectant), and rerinse the cage to remove the disinfectant. Discard all items that cannot be adequately disinfected (e.g., wooden perches, ropes, nest material, and litter). Minimize the circulation of feathers and dust by wet-mopping the floor frequently with disinfectants and preventing air currents and drafts within the area. Reduce contamination from dust by spraying the floor with a disinfectant or water before sweeping it. Do not use a vacuum cleaner, as it can aerosolize infectious particles. Frequently remove waste material from the cage (after moistening the material), and burn or double-bag the waste for disposal. Care for healthy birds before handling isolated or sick birds.
- **Use disinfection measures.** *C. psittaci* is susceptible to most disinfectants and detergents as well as heat; however, it is resistant to acid and alkali. A 1:1,000 dilution of quaternary ammonium compounds (e.g., Roccal® or Zephiran®) is effective, as is 70% isopropyl alcohol, 1% Lysol®, 1:100 dilution of household bleach (i.e., 2.5 tablespoons per gallon), or chlorophenols. Many disinfectants

are respiratory irritants and should be used in a well-ventilated area. Avoid mixing disinfectants with any other product.

Recommendations for Treating and Caring for Infected Birds

All birds with confirmed or probable AC should be isolated and treated, preferably under the supervision of a veterinarian (Appendix B). Birds with suspected AC or birds previously exposed to AC should be isolated and retested or treated. Because treated birds can be reinfected, they should not be exposed to untreated birds or other potential sources of infection. To prevent reinfection, contaminated aviaries should be thoroughly cleaned and sanitized. No AC vaccines are available.

The following general recommendations should be followed when treating and caring for birds with confirmed, probable, or suspected cases of AC:

- Protect birds from undue stress (e.g., chilling or shipping), poor husbandry, and malnutrition. These problems reduce the effectiveness of treatment and promote the development of secondary infections with other bacteria or yeast.
- Observe the birds daily, and weigh them every 3–7 days. If the birds are not maintaining weight, have them reevaluated by a veterinarian.
- Avoid high dietary concentrations of calcium and other divalent cations because they inhibit the absorption of tetracyclines. Remove oyster shell, mineral blocks, and cuttlebone.
- Isolate birds that are to be treated in clean, uncrowded cages.
- Clean up all spilled food promptly; wash food and water containers daily.
- Provide fresh water and appropriate vitamins daily.
- Continue medication for the full treatment period to avoid relapses. Birds can appear clinically improved and have reduced chlamydial shedding after 1 week.

Responsibilities of Physicians and Veterinarians

Persons exposed to birds with AC should seek medical attention if they develop influenza-like symptoms or other respiratory illness. The physician should collect specimens for laboratory analysis (see Part I) and initiate early and specific treatment for psittacosis. Most states require physicians to report cases of psittacosis to the appropriate state or local health authorities. Timely diagnosis and reporting can help identify the source of infection and control the spread of disease. Local and state authorities may conduct epidemiologic investigations and institute additional disease control measures (see Local and State Epidemiologic Investigations). Birds that are suspected sources of human infection should be referred to veterinarians for evaluation and treatment.

Veterinarians should be aware that AC is not a rare disease among pet birds. They should consider a diagnosis of AC for any lethargic bird that has nonspecific signs of illness, especially if the bird was purchased recently. If AC is suspected, the veterinarian should submit appropriate laboratory specimens to confirm the diagnosis. Laboratories and attending veterinarians should follow local and state regulations or guidelines

regarding case reporting. Veterinarians should work closely with authorities on investigations and inform clients that infected birds should be isolated and treated. In addition, they should educate clients about the public health hazard posed by AC and the appropriate precautions that should be taken to avoid the risk for transmission.

Quarantine of Birds

The appropriate animal and public health authorities may issue a quarantine for all affected and susceptible birds on a premises where *C. psittaci* infection has been identified. The purpose of imposing a quarantine is to prevent further disease transmission. Reasonable options should be made available to the owners and operators of pet stores. For example, with the approval of state or local authorities, the owner of quarantined birds may choose to a) treat the birds in a separate quarantine area to prevent exposure to the public and other birds, b) sell the birds if they have completed at least 7 days of treatment, provided that the new owner agrees in writing to continue the quarantine and treatment and is informed of the disease hazards, or c) euthanize the infected birds. After completion of the treatment or removal of the birds, a quarantine can be lifted when the infected premises are thoroughly cleaned and disinfected. The area can then be restocked with birds.

Bird Importation Regulations

The Veterinary Services of the Animal and Plant Health Inspection Service, U.S. Department of Agriculture (USDA), regulates the importation of pet birds to ensure that exotic poultry diseases are not introduced into the United States. These regulations are set forth in the *Code of Federal Regulations*, Title 9, Chapter 1 (5). Current minimum treatment protocols under these regulations are not always sufficient to clear AC from all birds. Illegally smuggled birds are also a source of new AC infection to domestic flocks. In general, current USDA regulations regarding the importation of birds include the following requirements:

- Before shipping the birds, the importer must obtain an import permit from the USDA and a health certificate issued and/or endorsed by a veterinarian of the national government of the exporting country.
- A USDA veterinary inspection must be conducted at the first port of entry in the United States and a quarantine be imposed for a minimum of 30 days at a USDA-approved facility to determine whether the birds are free of evidence of communicable diseases of poultry. In addition, the birds must be tested to ensure they are free of exotic Newcastle disease and pathogenic avian influenza.
- During the 30-day U.S. quarantine, psittacine birds must receive a balanced, medicated feed ration containing >1% chlortetracycline (CTC) with <0.7% calcium for the entire quarantine period as a precautionary measure against AC. The USDA recommends that importers continue CTC prophylactic treatment of psittacine birds for an additional 15 days (i.e., for 45 continuous days).

Local and State Epidemiologic Investigations

Public health or animal health authorities at the local or state level might need to conduct epidemiologic investigations to help control the transmission of *C. psittaci* to humans and birds. An epidemiologic investigation should be initiated if a) a bird with confirmed or probable AC was procured from a pet store, breeder, or dealer within 60 days of the onset of signs of illness, b) a person has confirmed or probable psittacosis, or c) several suspect avian cases have been identified from the same source. Other situations can be investigated at the discretion of the appropriate local or state public health department or animal health authorities.

Investigations involving recently purchased birds should include a visit to the site where the infected bird is located and identification of the location where the bird was originally procured (e.g., pet shop, dealer, breeder, or quarantine station). During such investigations, authorities should consider documenting the number and types of birds involved, the health status of potentially affected persons and birds, locations of facilities where birds were housed, relevant ventilation-related factors, and any treatment protocol. Examination of sales records for other birds that had contact with the infected bird may be considered. To help identify multistate outbreaks of *C. psittaci* infection, local and state authorities should report suspected outbreaks to the Respiratory Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, CDC, telephone (404) 639-2215.

References

1. CDC. Summary of notifiable diseases, United States, 1998. MMWR 1999;47(53).
2. CDC. Case definitions for infectious conditions under public health surveillance. MMWR 1997;46(No. RR-10):27.
3. Schlossberg D. *Chlamydia psittaci* (psittacosis). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th edition. New York, NY: Churchill Livingstone, 2000:2004-6.
4. Fudge AM. Avian chlamydiosis. In: Roskopf WJ Jr, Woerpel RW, eds. Diseases of cage and aviary birds. Baltimore, MD: Williams & Wilkins, 1996:572-85.
5. Animal and Plant Health Inspection Service, US Department of Agriculture. 9 CFR Part 93. Importation of certain animals, birds, and poultry, and certain animal, bird, and poultry products; requirements for means of conveyance and shipping containers. Subpart A — Birds. Code of Federal Regulations, January 1, 1999:100-6.

Additional Resources

- Flammer K. Chlamydia. In: Altman RB, Clubb SL, Dorrestein GM, Quesenberry K, eds. Avian medicine and surgery. Philadelphia, PA: WB Saunders, 1997:364-79.
- Fudge AM. A review of methods to detect *Chlamydia psittaci* in avian patients. J Avian Med Surg 1997;11:153-65.
- Gerlach H. Chlamydia. In: Ritchie BW, Harrison GJ, Harrison LR, eds. Avian medicine: principles and application. Lake Worth, FL: Wingers Publishing, 1994:984-96.
- Messmer TO, Skelton SK, Moroney JF, Daugharty H, Fields BS. Application of a nested, multiplex PCR to psittacosis outbreaks. J Clin Microbiol 1997;35:2043-6.
- Schaffner W. Birds of a feather — do they flock together? Infect Control Hosp Epidemiol 1997;18:162-4.

Appendix A

METHODS FOR DIAGNOSING AVIAN CHLAMYDIOSIS

Pathologic Findings

In birds that have avian chlamydiosis (AC), cloudy air sacs and an enlarged liver and spleen usually are observed, but no specific gross lesion is pathognomonic. The chromatic or immunologic staining of tissue-impression smears can be used to identify organisms.

Culture Technique

Isolation of the etiologic agent, *Chlamydia psittaci*, from the bird's spleen, liver, air sacs, pericardium, heart, or intestines is the optimal means for verifying the diagnosis. *Chlamydia* species are obligate intracellular bacteria that must be isolated in tissue culture, mice, or chick embryos. Specialized laboratory facilities and training are necessary for reliable identification of chlamydial isolates and adequate protection of microbiologists. Consequently, few laboratories perform chlamydial cultures.

In live birds, depending on which clinical signs they exhibit, combined choanal and cloacal swab specimens should be collected, refrigerated, and sent to the laboratory packed in ice but not frozen. The proper handling of samples is critical for maintaining the viability of organisms for culture, and a special transport medium is required. The diagnostic laboratory should be contacted for specific procedures required for collection and submission of specimens.

Live birds being screened for *C. psittaci* might not shed the microorganism daily. Therefore, to reduce laboratory costs, serial specimens should be collected for 3–5 consecutive days and pooled before being cultured. Tissue samples from the bird's liver and spleen are the preferred necropsy specimens for isolation of *C. psittaci*. Use of culture is recommended to avoid limitations associated with other tests.

Tests for Antibody

A positive serologic test result is evidence that the bird was infected by *C. psittaci* at some point, but it might not indicate that the bird has an active infection. False-negative results can occur for birds that have acute infection when they are sampled before seroconversion. Treatment with an antimicrobial agent can diminish the antibody response.

A single testing method might not be adequate because of the diversity of reactions with immunoglobulins from the various avian species. Therefore, use of a combination of antibody- and antigen-detection methods is recommended, particularly when only one bird is tested. When specimens are obtained from a single bird, serologic testing is most useful when a) signs of disease and the history of the flock or aviary are considered and b) serologic results are compared with the white blood cell counts and liver-enzyme activities. A greater than fourfold increase in titer of paired samples or a combination of a titer and antigen identification is needed to confirm a diagnosis of AC.

Some of the advantages and disadvantages of two serologic tests for antibodies are described in the following sections.

Direct Complement Fixation (CF)

Direct CF is more sensitive than agglutination methods. False-negative results are possible in specimens from small psittacine birds (e.g., budgerigars, young African grey parrots, and lovebirds). High titers can persist after treatment and complicate interpretation of subsequent tests. Modified direct CF is more sensitive than direct CF.

Elementary-Body Agglutination (EBA)

EBA is commercially available and can detect early infection. Titers >10 in budgerigars, cockatiels, and lovebirds and titers >20 in larger birds are frequently seen in cases of recent infection. However, elevated titers can persist after treatment is completed.

Tests for Antigen

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA tests (e.g., QuickView[®]) were originally developed for identification of *Chlamydia trachomatis* in humans. The exact sensitivity and specificity of these tests for identifying *C. psittaci* are not known. They are now used to identify *C. psittaci* in birds. These tests give rapid results and do not require live, viable organisms; however, false-positive results from cross-reacting antigens can occur. False-negative results can occur if insufficient antigen is present. As with all nonculture tests, the results must be evaluated in conjunction with clinical findings. If a bird has a positive ELISA result but is clinically healthy, the veterinarian should attempt to verify that the bird is shedding antigen through isolation of the organism. When a clinically ill bird has a negative ELISA result, a diagnosis of AC cannot be excluded without further testing (e.g., culture, serologic testing, or polymerase chain reaction).

Immunofluorescent Antibody Tests (IFA)

Monoclonal or polyclonal antibodies, fluorescein-staining techniques, and fluorescent microscopy are used to identify the organism in impression smears or other specimens. These tests have similar advantages and disadvantages as ELISA.

Polymerase Chain Reaction (PCR)

Numerous laboratories offer diagnostic testing using PCR technology. The PCR test promises to be sensitive and specific for detection of target DNA sequences in collected specimens (e.g., choanal and cloacal swabs, blood). Results from tests that have not been validated can be difficult to interpret.

Additional Tests

Additional diagnostic techniques are in use or under development. Readers are encouraged to research peer-reviewed reports on such tests before use.

Laboratories that Test Avian Specimens for *C. psittaci*

Many state diagnostic laboratories and veterinary colleges perform routine chlamydial diagnostics. Additional laboratories are included in the following list (Table A). Other sources might be available. Inclusion in Table A does not imply endorsement by the Committee of the National Association of State Public Health Veterinarians or constituent institutions.

TABLE A. Laboratories that test avian specimens for *Chlamydia psittaci*

Laboratory	Tests performed*	Phone number
Animal Health Diagnostic Laboratory, East Lansing, Michigan	<ul style="list-style-type: none"> • ELISA (antigen) • PCR (DNA probe) • Culture 	(517) 353-2296
ANTECH Diagnostics Farmingdale, New York	<ul style="list-style-type: none"> • Fecal antigen • Serum antibody titer • IFA 	(800) 872-7828
Avian and Exotic Animal Clin Path Labs, Santa Monica, California	<ul style="list-style-type: none"> • PCR (DNA probe) (Ohio) • EBA (Texas) 	(310) 542-6556
California Avian Laboratory, Citrus Heights, California	<ul style="list-style-type: none"> • Fluorescent antibody 	(800) 783-2473
Comparative Pathology Laboratory, University of Miami School of Medicine, Miami, Florida	<ul style="list-style-type: none"> • ELISA (antigen) • EBA • CF • IFA (antibody) • PCR (DNA probe) 	(800) 596-7390
Infectious Diseases Laboratory, University of Georgia, College of Veterinary Medicine, Athens, Georgia	<ul style="list-style-type: none"> • Culture • Cytology • PCR (DNA probe) • IFA (Florida) 	(706) 542-8092
Research Associates Laboratory, Milford, Ohio	<ul style="list-style-type: none"> • PCR (DNA probe) 	(513) 248-4700
Texas Veterinary Medical Diagnostic Laboratory, College Station, Texas	<ul style="list-style-type: none"> • Culture • PCR (DNA probe) • Gimenez stain • EBA • CF 	(409) 845-3414

* CF = complement fixation; EBA = elementary-body agglutination; ELISA = enzyme-linked immunosorbent assay; IFA = immunofluorescent antibody tests; PCR = polymerase chain reaction.

Appendix B

TREATMENT OPTIONS FOR PET BIRDS WITH AVIAN CHLAMYDIOSIS

Although these treatment protocols are usually successful, knowledge is evolving and no protocol assures safe treatment or complete elimination of infection. Therefore, treatment for avian chlamydiosis (AC) should be supervised by a licensed veterinarian. In quarantine situations, compliance might be easiest to monitor when treatment is provided by medicated feed. All birds with AC should be treated for 45 days, except as noted in the following sections.

Medicated Feed

Medicated feed should be the only food provided to the birds during the entire treatment. Birds' acceptance of medicated feed is variable. Thus, food consumption should be monitored. Acceptance can be enhanced by first adapting the birds to a similar, nonmedicated diet. Treatment begins when the birds accept the medicated feed as the sole food in their diet. The following options are available:

- Medicated mash diets (i.e., >1% chlortetracycline [CTC] with <0.7% calcium) prepared with corn, rice, and hen's scratch can be used.
- Pellets and extruded products containing 1% CTC can be used. They are available and appropriate for use with most pet birds. Select a pellet size appropriate for the size of bird being treated.
- A special diet might be necessary for lorries and lorikeets, which feed on nectar and fruit in the wild.

Medicated Water

Limited pharmacological studies indicate that dosages of 400 mg doxycycline hyclate/liter of water in cockatiels and 400–600 mg/liter of water in African grey parrots, blue-fronted Amazon parrots, and Goffin's cockatoos will maintain therapeutic concentrations (Keven Flammer, North Carolina State University, unpublished data, 2000). Research data are lacking for other species, but empiric use of 400-mg/liter of water has been successful for many psittacine birds (excluding budgerigars). Drug toxicity can occur when using this regimen, so an experienced avian veterinarian should monitor birds during treatment. Signs of toxicity include general signs of illness (depression, inactivity, decreased appetite), green or yellow stained urine, and altered hepatic tests (elevated aspartate aminotransferase [AST], lactate dehydrogenase [LD], and bile acids). If toxicity occurs, medication should be immediately stopped and supportive care provided until the bird recovers. Treatment with a different regimen can be started at a later date.

Oral Doxycycline

Doxycycline is the drug of choice for oral treatment; either the monohydrate or calcium-syrup formulations can be used. Dosage recommendations are as follows: 40–50 mg/kg body weight by mouth once a day for cockatiels, Senegal parrots, and blue-fronted and orange-winged Amazon parrots; and 25 mg/kg body weight by mouth once a day for African grey parrots, Goffin's cockatoos, blue and gold macaws, and green-winged macaws. Precise dosages cannot be extrapolated for other species; however, 25–30 mg/kg body weight administered by mouth once a day is the recommended starting dosage for cockatoos and macaws, and 25–50 mg/kg by mouth once a day is recommended for other psittacine species. If the bird regurgitates the drug, another treatment method should be used.

Injectable Doxycycline

Intramuscular (IM) injection into the pectoral muscle is often the easiest method of treatment, but not all injectable doxycycline formulations are suitable for IM injection. All available formulations can cause irritation at the injection site. The Vibrovenos® formulation (Pfizer Laboratories, London) is available in Europe and is effective if administered at doses of 75–100 mg/kg body weight IM every 5–7 days for the first 4 weeks and subsequently every 5 days for the duration of treatment. The injectable hyclate formulation labeled for intravenous (IV) use in humans can be used IV in birds. This formulation is not suitable for IM use because severe tissue reactions will occur at the site of injection.

Injectable Oxytetracycline

Limited information exists for the use of an injectable, long-acting oxytetracycline product (LA-200®; Pfizer Laboratories, Exton, Pennsylvania). Current dosage recommendations are as follows: subcutaneous injection of 75 mg/kg body weight every 3 days in Goffin's cockatoos, blue-fronted and orange-winged Amazon parrots, and blue and gold macaws. This dosage might be suitable for but has not been tested on other species. This product causes irritation at the site of injection and is best used to initiate treatment in ill birds or those that are reluctant to eat. After stabilization with oxytetracycline treatment, the birds should be switched to another form of treatment to reduce the muscle irritation that is caused by repeated oxytetracycline injection.

Experimental Methods

Treatment protocols using late-generation macrolides and pharmacist-compounded injectable doxycycline are under investigation. Information about these treatment protocols might be available in the scientific literature or from avian veterinary specialists.

Sources of Medications

The following sources (Table B) are not listed as an endorsement of the companies or products. Other sources might be available.

TABLE B. Sources of medication for avian chlamydiosis

Contact	Product	Phone number
Medicated feed		
Avi-Sci Inc., St. Johns, Michigan	Chlortetracycline, 1%	(800) 942-3438
Pretty Bird International, Inc., Stacy, Minnesota	Chlortetracycline, 1%	(800) 356-5020
Rolf C. Hagen, Mansfield, Massachusetts	Chlortetracycline, 1%	(800) 225-2700 (888) 294-2436
Roudybush, Paso Robles, California	Chlortetracycline, 1%	(800) 326-1726
Ziegler Brothers, Inc., Gardners, Pennsylvania	Chlortetracycline, 1%	(800) 841-6800
Chlortetracycline for mash diets		
Fort Dodge Animal Health, Fort Dodge, Iowa	Aureomycin soluble powder concentrate, 64 gm/25.6 oz	(877) 747-2030
Pfizer Animal Health Group, Exton, Pennsylvania	CLTC 100 MR, 22% — 100 gm/lb	(800) 438-1985
DurVet, Blue Springs, Missouri	CTC-50 and CTC soluble powder, 25.6 oz.	(800) 821-5570
Doxycycline*		
Pfizer, New York, New York	Vibramycin IV, 100 or 200 mg	(800) 438-1985
Wyeth-Ayerst Laboratories Radnor, Pennsylvania	Doxycycline, 100 or 200 mg	(610) 902-1200
American Pharmaceutical Partners, Los Angeles, California	Doxycycline, 100 mg	(888) 391-6300
Gerry Dorrestein, D.V.M., Ph.D., Faculty, Universiteit Utrecht, Veterinary Medicine, Utrecht, Netherlands	Vibrovenos intramuscular doxycycline injection [†]	011 31 30 2290478 011 31 30 2534357 g.m.dorrestein@vet.uu.nl

* Powder for injection as hyclate.

† Investigational New Animal Drug Application (INADA) waiver required to ship this drug into the United States.

**Compendium of Animal Rabies Prevention
and Control, 2000**

**National Association of State Public Health
Veterinarians, Inc.**

Compendium of Animal Rabies Prevention and Control, 2000

National Association of State Public Health Veterinarians, Inc.*

The purpose of this Compendium is to provide rabies information to veterinarians, public health officials, and others concerned with rabies prevention and control. These recommendations serve as the basis for animal rabies-control programs throughout the United States and facilitate standardization of procedures among jurisdictions, thereby contributing to an effective national rabies-control program. This document is reviewed annually and revised as necessary. Immunization procedure recommendations are contained in Part I; all animal rabies vaccines licensed by the United States Department of Agriculture (USDA) and marketed in the United States are listed in Part II; Part III details the principles of rabies control.

Part I: Recommendations for Parenteral Immunization Procedures

A. Vaccine Administration

All animal rabies vaccines should be restricted to use by, or under the direct supervision of, a veterinarian.

B. Vaccine Selection

Part II lists all vaccines licensed by USDA and marketed in the United States at the time of publication. New vaccine approvals or changes in label specifications made subsequent to publication should be considered as part of this list. Vaccines used in state and local rabies-control programs should have a 3-year duration of immunity. This constitutes the most effective method of increasing the proportion of immunized dogs and cats in any population.

*THE NASPHV COMMITTEE: Suzanne R. Jenkins, VMD, MPH, Chair; Michael Auslander, DVM, MSPH; Lisa Conti, DVM, MPH; Robert H. Johnson, DVM; Mira J. Leslie, DVM; Faye E. Sorhage, VMD, MPH. CONSULTANTS TO THE COMMITTEE: Deborah J. Briggs, PhD; Kansas State University Rabies Laboratory; James E. Childs, ScD, CDC; Mary Currier, MD, MPH, Council of State and Territorial Epidemiologists (CSTE); Nancy Frank, DVM, MPH, American Veterinary Medical Association (AVMA), Council on Public Health and Regulatory Veterinary Medicine; Barry Watson, DVM, Animal Health Institute; Robert B. Miller, DVM, MPH, Animal and Plant Health Inspection Service, United States Department of Agriculture; Charles E. Rupprecht, VMD, PhD, CDC; Charles V. Trimarchi, MS, New York State Health Department. ENDORSED BY: AVMA and CSTE.

Address all correspondence to: Suzanne R. Jenkins, VMD, MPH, Virginia Department of Health, Office of Epidemiology, P.O. Box 2448, Room 113, Richmond, VA 23218.

C. Route of Inoculation

All vaccines must be administered in accordance with the specifications of the product label or package insert. Adverse reactions and vaccine failures should be reported to USDA, Animal and Plant Health Inspection Service, Center for Veterinary Biologics at (800) 752-6255 or by e-mail at CVB@usda.gov.

D. Vaccination of Wildlife and Hybrid Animals

The efficacy of parenteral rabies vaccination of wildlife and hybrids (the offspring of wild animals crossbred to domestic dogs and cats) has not been established, and no such vaccine is licensed for these animals. Zoos or research institutions may establish vaccination programs that attempt to protect valuable animals, but these programs should not replace appropriate public health activities that protect humans.

E. Accidental Human Exposure to Vaccine

Accidental inoculation might occur during administration of animal rabies vaccine. Such exposure to vaccines listed in Part II constitutes no rabies hazard.

F. Identification of Vaccinated Animals

All agencies and veterinarians should adopt the standard tag system. This practice will aid the administration of local, state, national, and international control procedures. Animal license tags should be distinguishable in shape and color from rabies tags. Anodized aluminum rabies tags should be no less than 0.064 inches in thickness.

1. Rabies Tags.

Calendar year	Color	Shape
2000	Red	Heart
2001	Blue	Rosette
2002	Orange	Oval
2003	Green	Bell

- 2. Rabies Certificate.** All agencies and veterinarians should use the National Association of State Public Health Veterinarians, Inc. Form #51, Rabies Vaccination Certificate, which can be obtained from vaccine manufacturers. Computer-generated forms containing the same information are acceptable.

Part II: Rabies vaccines licensed and marketed in the United States and NASPHV* recommendations, 2000

Product name	Produced by	Marketed by	For use in	Dosage (mL)	Age at primary vaccination†	Booster recommended	Route of inoculation
A) MONOVALENT (Inactivated)							
TRIMUNE	Fort Dodge Animal Health License No. 112	Fort Dodge Animal Health	Dogs	1	3 mos	1 yr later & triennially	IM [§]
			Cats	1	3 mos	1 yr later & triennially	IM
ANNUMUNE	Fort Dodge Animal Health License No. 112	Fort Dodge Animal Health	Dogs	1	3 mos	Annually	IM
			Cats	1	3 mos	Annually	IM
DEFENSOR 1	Pfizer, Inc. License No. 189	Pfizer, Inc.	Dogs	1	3 mos	Annually	IM or SC [¶]
			Cats	1	3 mos	Annually	SC
DEFENSOR 3	Pfizer, Inc. License No. 189	Pfizer, Inc.	Dogs	1	3 mos	1 yr later & triennially	IM or SC
			Cats	1	3 mos	1 yr later & triennially	SC
			Sheep	2	3 mos	Annually	IM
			Cattle	2	3 mos	Annually	IM
RABDOMUN	Pfizer, Inc. License No. 189	Schering-Plough	Dogs	1	3 mos	1 yr later & triennially	IM or SC
			Cats	1	3 mos	1 yr later & triennially	SC
			Sheep	2	3 mos	Annually	IM
			Cattle	2	3 mos	Annually	IM
RABDOMUN 1	Pfizer, Inc. License No. 189	Schering-Plough	Dogs	1	3 mos	Annually	IM or SC
			Cats	1	3 mos	Annually	SC
RABVAC 1	Fort Dodge Animal Health License No. 112	Fort Dodge Animal Health	Dogs	1	3 mos	Annually	IM or SC
			Cats	1	3 mos	Annually	IM or SC
RABVAC 3	Fort Dodge Animal Health License No. 112	Fort Dodge Animal Health	Dogs	1	3 mos	1 yr later & triennially	IM or SC
			Cats	1	3 mos	1 yr later & triennially	IM or SC
			Horses	2	3 mos	Annually	IM
PRORAB-1	Intervet, Inc. License No. 286	Intervet, Inc.	Dogs	1	3 mos	Annually	IM or SC
			Cats	1	3 mos	Annually	IM or SC
			Sheep	2	3 mos	Annually	IM
PRORAB-3F	Intervet, Inc. License No. 286	Intervet, Inc.	Cats	1	3 mos	1 yr later & triennially	IM or SC
IMRAB 3	Merial, Inc. License No. 298	Merial, Inc.	Dogs	1	3 mos	1 yr later & triennially	IM or SC
			Cats	1	3 mos	1 yr later & triennially	IM or SC
			Sheep	2	3 mos	1 yr later & triennially	IM or SC
			Cattle	2	3 mos	Annually	IM or SC
			Horses	2	3 mos	Annually	IM or SC
			Ferrets	1	3 mos	Annually	SC
IMRAB BOVINE PLUS	Merial, Inc. License No. 298	Merial, Inc.	Cattle	2	3 mos	Annually	IM or SC
			Horses	2	3 mos	Annually	IM or SC
			Sheep	2	3 mos	1 yr later & triennially	IM or SC
IMRAB 1	Merial, Inc. License No. 298	Merial, Inc.	Dogs	1	3 mos	Annually	IM or SC
			Cats	1	3 mos	Annually	IM or SC

Part II: (Continued) Rabies vaccines licensed and marketed in the United States and NASPHV* recommendations, 2000

Product name	Produced by	Marketed by	For use in	Dosage (mL)	Age at primary vaccination†	Booster recommended	Route of inoculation
B) MONOVALENT (Rabies glycoprotein, live canary pox vector)							
PUREVAX Feline Rabies	Merial, Inc. License No. 298	Merial, Inc.	Cats	1	8 wks	Annually	SC
C) COMBINATION (Inactivated rabies)							
ECLIPSE 3 + FeLV/R	Fort Dodge Animal Health License No. 112	Schering-Plough	Cats	1	3 mos	Annually	IM or SC
ECLIPSE 4 + FeLV/R	Fort Dodge Animal Health License No. 112	Schering-Plough	Cats	1	3 mos	Annually	IM or SC
Fel-O-Guard 3 + FeLV/R	Fort Dodge Animal Health License No. 112	Fort Dodge Animal Health	Cats	1	3 mos	Annually	IM or SC
Fel-O-Guard 4 + FeLV/R	Fort Dodge Animal Health License No. 112	Fort Dodge Animal Health	Cats	1	3 mos	Annually	IM or SC
Fel-O-Vax PCT-R	Fort Dodge Animal Health License No. 112	Fort Dodge Animal Health	Cats	1	3 mos	1 yr later & triennially	IM
Feline 3 + IMRAB	Merial, Inc. License No. 298	Merial, Inc.	Cats	1	3 mos	1 yr later & triennially	SC
Feline 4 + IMRAB	Merial, Inc. License No. 298	Merial, Inc.	Cats	1	3 mos	1 yr later & triennially	SC
IMRAB Booster + C4	Merial, Inc. License No. 298	Merial, Inc.	Dogs	1	8 wks	Annually	SC
IMRAB Booster + C4/CV	Merial, Inc. License No. 298	Merial, Inc.	Dogs	1	8 wks	Annually	SC
IMRAB Booster + C6	Merial, Inc. License No. 298	Merial, Inc.	Dogs	1	8 wks	Annually	SC
IMRAB Booster + C6/CV	Merial, Inc. License No. 298	Merial, Inc.	Dogs	1	8 wks	Annually	SC
MYSTIQUE II	Bayer Corp. License No. 52	Bayer Corp.	Horses	1	3 mos	Annually	IM
POTOMAVAC+ EQUINE	Merial, Inc.	Merial, Inc.	Horses	1	3 mos	Annually	IM
POTOMAVAC + IMRAB	Merial, Inc. License No. 298	Merial, Inc.	Horses	1	3 mos	Annually	IM

Part II: (Continued) Rabies vaccines licensed and marketed in the United States and NASPHV* recommendations, 2000

Product name	Produced by	Marketed by	For use in	Dosage (mL)	Age at primary vaccination [†]	Booster recommended	Route of inoculation
D) COMBINATION (Rabies glycoprotein, live canary pox vector)							
PUREVAX Feline 3/ Rabies	Merial, Inc. License No. 298	Merial, Inc.	Cats	1	8 wks	Annually	SC
PUREVAX Feline 3/ Rabies + LEUCAT	Merial, Inc. License No. 298	Merial, Inc.	Cats	1	8 wks	Annually	SC
PUREVAX Feline 4/ Rabies	Merial, Inc. License No. 298	Merial, Inc.	Cats	1	8 wks	Annually	SC
PUREVAX Feline 4/ Rabies + LEUCAT	Merial, Inc. License No. 298	Merial, Inc.	Cats	1	8 wks	Annually	SC
E) ORAL (Rabies glycoprotein, live vaccinia vector) - RESTRICTED TO USE IN STATE AND FEDERAL RABIES CONTROL PROGRAMS							
RABORAL V-RG	Merial, Inc. License No. 298	Merial, Inc.	Raccoons	N/A	N/A	As determined by local authorities	Oral

* National Association of State Public Health Veterinarians, Inc.

[†] Minimum age (or older) and revaccinated 1 year later.

[§] Intramuscularly.

[¶] Subcutaneously.

Part III: Rabies Control

A. Principles of Rabies Control

1. **Rabies Exposure.** Rabies is transmitted only when the virus is introduced into bite wounds, open cuts in skin, or onto mucous membranes.
2. **Human Rabies Prevention.** Rabies in humans can be prevented either by eliminating exposures to rabid animals or by providing exposed persons with prompt local treatment of wounds combined with appropriate passive and active immunization. The rationale for recommending preexposure and postexposure rabies prophylaxis and details of their administration can be found in the current recommendations of the Advisory Committee on Immunization Practices (ACIP).^{*} These recommendations, along with information concerning the current local and regional status of animal rabies and the availability of human rabies biologics, are available from state health departments.
3. **Domestic Animals.** Local governments should initiate and maintain effective programs to ensure vaccination of all dogs, cats, and ferrets and to remove strays and unwanted animals. Such procedures in the United States have reduced laboratory-confirmed cases of rabies in dogs from 6,949 in 1947 to 113 in 1998. Because more rabies cases are reported annually involving cats (282 in 1998) than dogs, vaccination of cats should be required. The recommended vaccination procedures and the licensed animal vaccines are specified in Parts I and II of the Compendium.
4. **Rabies in Wildlife.** The control of rabies among wildlife reservoirs is difficult. Vaccination of free-ranging wildlife or selective population reduction might be useful in some situations, but the success of such procedures depends on the circumstances surrounding each rabies outbreak. (See Part III.C. Control Methods in Wildlife.)
5. **Rabies Serology.** Evidence of circulating rabies virus neutralizing antibodies should not be used as a substitute for current vaccination in managing rabies exposures or determining the need for booster vaccinations.

B. Control Methods in Domestic and Confined Animals

1. **Preexposure Vaccination and Management.** Parenteral animal rabies vaccines should be administered only by, or under the direct supervision of, a veterinarian. This is the only way to ensure that a responsible person can be held accountable to assure the public that the animal has been properly vaccinated. Within 1 month after primary vaccination, a peak rabies antibody titer is reached, and the animal can be considered immunized. An animal is currently vaccinated and is considered immunized if the primary vaccination was administered at least 30 days previously and vaccinations have been administered in accordance with this Compendium. Regardless of the age of the animal at initial vaccination, a second vaccination should be administered 1 year later. (See Parts I and II for recommended vaccines and procedures).

^{*}CDC. Human rabies prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-1).

NASPHV Form #51, Rabies Vaccination Certificate. When an interstate health certificate or certificate of veterinary inspection is required, it should contain the same rabies vaccination information as Form #51.

4. **Adjunct Procedures.** Methods or procedures that enhance rabies control include the following:
 - a. **Licensure.** Registration or licensure of all dogs, cats, and ferrets may be used to aid in rabies control. A fee is frequently charged for such licensure, and revenues collected are used to maintain rabies- or animal-control programs. Vaccination is an essential prerequisite to licensure.
 - b. **Canvassing of Area.** House-to-house canvassing by animal-control personnel facilitates enforcement of vaccination and licensure requirements.
 - c. **Citations.** Citations are legal summonses issued to owners for violations, including the failure to vaccinate or license their animals. The authority for officers to issue citations should be an integral part of each animal-control program.
 - d. **Animal Control.** All communities should incorporate stray animal control, leash laws, and training of personnel in their programs.
5. **Postexposure Management.** Any animal potentially exposed to rabies virus (See Part III.A.1. Rabies Exposure) by a wild, carnivorous mammal or a bat that is not available for testing should be regarded as having been exposed to rabies.
 - a. **Dogs, Cats, and Ferrets.** Unvaccinated dogs, cats, and ferrets exposed to a rabid animal should be euthanized immediately. If the owner is unwilling to have this done, the animal should be placed in strict isolation for 6 months and vaccinated 1 month before being released. Animals with expired vaccinations need to be evaluated on a case-by-case basis. Dogs, cats, and ferrets that are currently vaccinated should be revaccinated immediately, kept under the owner's control, and observed for 45 days.
 - b. **Livestock.** All species of livestock are susceptible to rabies; cattle and horses are among the most frequently infected. Livestock exposed to a rabid animal and currently vaccinated with a vaccine approved by USDA for that species should be revaccinated immediately and observed for 45 days. Unvaccinated livestock should be slaughtered immediately. If the owner is unwilling to have this done, the animal should be kept under close observation for 6 months. The following are recommendations for owners of unvaccinated livestock exposed to rabid animals:
 - 1) If the animal is slaughtered within 7 days of being bitten, its tissues may be eaten without risk for infection, provided that liberal portions of the exposed area are discarded. Federal meat inspectors must reject for slaughter any animal known to have been exposed to rabies within 8 months.
 - 2) Neither tissues nor milk from a rabid animal should be used for human or animal consumption. Pasteurization temperatures will inactivate rabies virus; therefore, drinking pasteurized milk or eating cooked meat does not constitute a rabies exposure.
 - 3) Having more than one rabid animal in a herd or having herbivore-to-herbivore transmission is rare; therefore, restricting the rest of the herd if a single animal has been exposed to or infected by rabies might not be necessary.

- c. **Other Animals.** Other animals bitten by a rabid animal should be euthanized immediately. Animals maintained in USDA-licensed research facilities or accredited zoological parks should be evaluated on a case-by-case basis.
- 6. Management of Animals That Bite Humans.**
- a. A healthy dog, cat, or ferret that bites a person should be confined and observed daily for 10 days; administration of rabies vaccine is not recommended during the observation period. Such animals should be evaluated by a veterinarian at the first sign of illness during confinement. Any illness in the animal should be reported immediately to the local health department. If signs suggestive of rabies develop, the animal should be euthanized, its head removed, and the head shipped under refrigeration (not frozen) for examination of the brain by a qualified laboratory designated by the local or state health department. Any stray or unwanted dog, cat, or ferret that bites a person may be euthanized immediately and the head submitted as described above for rabies examination.
 - b. Other biting animals that might have exposed a person to rabies should be reported immediately to the local health department. Prior vaccination of an animal might not preclude the necessity for euthanasia and testing if the period of virus shedding is unknown for that species. Management of animals other than dogs, cats, and ferrets depends on the species, the circumstances of the bite, the epidemiology of rabies in the area, and the biting animal's history, current health status, and potential for exposure to rabies.

C. Control Methods in Wildlife

The public should be warned not to handle wildlife. Wild mammals and hybrids that bite or otherwise expose persons, pets, or livestock should be considered for euthanasia and rabies examination. A person bitten by any wild mammal should immediately report the incident to a physician who can evaluate the need for antirabies treatment (See current rabies prophylaxis recommendations of the ACIP*). State-regulated wildlife rehabilitators may play a role in a comprehensive rabies-control program. Minimum standards for persons who rehabilitate wild mammals should include receipt of rabies vaccination, appropriate training, and continuing education.

1. **Terrestrial Mammals.** The use of licensed oral vaccines for the mass immunization of free-ranging wildlife should be considered in selected situations, with the approval of the state agency responsible for animal rabies control. Continuous and persistent government-funded programs for trapping or poisoning wildlife are not cost effective in reducing wildlife rabies reservoirs on a statewide basis. However, limited control in high-contact areas (e.g., picnic grounds, camps, or suburban areas) may be indicated for the removal of selected high-risk species of wildlife. The state wildlife agency and state health department should be consulted for coordination of any proposed vaccination or population-reduction programs.
2. **Bats.** Indigenous rabid bats have been reported from every state except Hawaii and have caused rabies in at least 33 humans in the United States. Bats should

*CDC. Human rabies prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-1).

be excluded from houses and adjacent structures to prevent direct association with humans. Such structures should then be made bat-proof by sealing entrances used by bats. Controlling rabies in bats by programs designed to reduce bat populations is neither feasible nor desirable.

MMWR

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov> or from CDC's file transfer protocol server at <ftp.cdc.gov>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

☆U.S. Government Printing Office: 2000-533-206/28022 Region IV